Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention

Antimicrobial Agents and Chemotherapy
Stephanie E BarrettMarian E Gindy

Abstract

Regimen adherence remains a major hurdle to the success of daily oral drug regimens for the treatment and prevention of human immunodeficiency virus (HIV) infection. Long-acting drug formulations requiring less-frequent dosing offer an opportunity to improve adherence and allow for more forgiving options with regard to missed doses. The administration of long-acting formulations in a clinical setting enables health care providers to directly track adherence. MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine [EFdA]) is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) drug candidate under investigation as part of a regimen for HIV treatment, with potential utility as a single agent for preexposure prophylaxis (PrEP). The active triphosphate of MK-8591 (MK-8591-TP) exhibits protracted intracellular persistence and, together with the potency of MK-8591, supports its consideration for extended-duration dosing. Toward this end, drug-eluting implant devices were designed to provide prolonged MK-8591 release in vitro and in vivo Implants, administered subcutaneously, were studied in rodents and nonhuman primates to establish MK-8591 pharmacokinetics and intracellular levels of MK-8591-TP. These data were...Continue Reading

References

Jan 1, 1997·AIDS Clinical Review·S G Deeks, P A Volberding
Jan 16, 2003·Biomaterials·Chien Chung ChenSheng Yang Lee
Aug 15, 2006·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA panel
Mar 31, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Lieven BaertJan Rosier
Feb 18, 2010·Antimicrobial Agents and Chemotherapy·Gerben van 't KloosterLieven Baert
Nov 26, 2010·The New England Journal of Medicine·Robert M GrantUNKNOWN iPrEx Study Team
May 12, 2012·Polymers·Hirenkumar K Makadia, Steven J Siegel
Sep 14, 2012·Science Translational Medicine·Peter L AndersonUNKNOWN iPrEx Study Team
Feb 16, 2013·Drugs·Sharon L Karmon, Martin Markowitz
Apr 26, 2013·Current Opinion in HIV and AIDS·David T Evans, Guido Silvestri
Oct 9, 2013·Current Opinion in HIV and AIDS·William R SpreenJohn C Pottage
Aug 27, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Amy L CorneliUNKNOWN FEM-PrEP Study Group
Apr 22, 2015·Antimicrobial Agents and Chemotherapy·Manjula GunawardanaMarc M Baum
Jun 14, 2015·Virology Journal·Tara R HenningEllen N Kersh
Nov 7, 2015·AIDS·Ariane van der StratenUNKNOWN Microbicide Trials Network-003D Study Team
Feb 24, 2016·The New England Journal of Medicine·Jared M BaetenUNKNOWN MTN-020–ASPIRE Study Team
Jun 2, 2016·Journal of the International AIDS Society·Ellen H LueckeUNKNOWN MTN-003D Study Team
Dec 14, 2016·The New England Journal of Medicine·Annalene NelUNKNOWN Ring Study Team
Jun 15, 2017·Drug Delivery and Translational Research·William R LykinsTejal A Desai
Apr 27, 2018·Current Opinion in HIV and AIDS·Martin Markowitz, Stefan G Sarafianos

❮ Previous
Next ❯

Citations

Sep 11, 2018·Clinical Pharmacology and Therapeutics·Craig W Hendrix
Nov 10, 2018·Clinical Pharmacology and Therapeutics·Charles Flexner
Jan 25, 2019·Expert Opinion on Pharmacotherapy·Amedeo Capetti, Giuliano Rizzardini
Oct 26, 2018·Annual Review of Medicine·Roy M Gulick, Charles Flexner
Aug 20, 2019·Current Topics in Medicinal Chemistry·Kenji MaedaHiroaki Takeuchi
Nov 28, 2019·Expert Review of Clinical Pharmacology·Mary Clare MastersSusan E Cohn
Feb 14, 2020·Current HIV/AIDS Reports·Mary C Cambou, Raphael J Landovitz
Jul 28, 2020·Chemistry : a European Journal·Aaron WhittakerHeather C Johnson
Jun 9, 2019·The Journal of Infectious Diseases·Martin MarkowitzJay A Grobler
Mar 29, 2020·Culture, Health & Sexuality·Emily A KrogstadLinda-Gail Bekker
Apr 29, 2020·Nature Materials·Tanmay A KulkarniHoward E Gendelman
Nov 21, 2019·Southern African Journal of HIV Medicine·Mohendran ArcharyAmy Slogrove
Apr 24, 2019·Pharmaceuticals·Kamal SinghAnders Sönnerborg
Aug 4, 2019·Pharmaceutics·M Melissa PeetMeredith R Clark
Dec 5, 2020·Expert Opinion on Drug Delivery·Ashley R JohnsonStephanie E Barrett
Dec 11, 2020·Polymers·Cintya DharmayantiAnton Blencowe
Nov 21, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Duy-Khiet HoPatrick S Stayton
Dec 22, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dipu KarunakaranPatrick F Kiser
Nov 12, 2020·Current Opinion in Pharmacology·Yali SangFener Chen
Sep 29, 2019·The Lancet. HIV·Lara Esteves CoelhoBeatriz Grinsztejn
Jan 5, 2021·International Journal of Pharmaceutics: X·Panita MaturavongsaditS Rahima Benhabbour
Dec 19, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Juliana C QuartermanAliasger K Salem
Nov 10, 2020·International Journal of Antimicrobial Agents·Charles FlexnerSusan Swindells
Jan 29, 2021·Chemical Reviews·Maria E CilentoStefan G Sarafianos
May 20, 2021·The Journal of Antimicrobial Chemotherapy·Richard E HaalandWalid Heneine
Apr 9, 2021·Advanced Drug Delivery Reviews·Alejandro J ParedesRyan F Donnelly
Jun 30, 2021·Advanced Drug Delivery Reviews·Sai Archana KroviAriane van der Straten
Jul 4, 2021·International Journal of Pharmaceutics·Panita MaturavongsaditS Rahima Benhabbour
Aug 16, 2021·International Journal of Pharmaceutics·Sarah A StewartEneko Larrañeta
Jul 8, 2020·Current Pharmaceutical Design·Somaraju R KumarUsha Y Nayak

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.